Cycloserine

PreclinicalSmall molecule

UUniversity of Calgary

Cycloserine is one of 70 small molecule programs targeting Smoking Behavior. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Smoking BehaviorActive, not recruiting

Pulmonary TuberculosisActive, not recruiting

TreatmentCompleted

Smoking BehaviorPreclinical

Active, not recruiting

Pulmonary TuberculosisPreclinical

Active, not recruiting

TreatmentPreclinical

Completed

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Dexilant

Takeda

Preclinical

2 2

Alfenta

Jazz Pharmaceuticals

Preclinical

1 3

Theo-Dur

Pfizer

Preclinical

1 4

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 5

Foscavir

CClinigen, Inc.

Preclinical

6 6

Valium

Akero Therapeutics

Preclinical

2 7

Lotemax

PPharmos

Preclinical

1 8

Norpramin

VValidus Pharmaceuticals

Preclinical

1 9

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 10

Crixivan

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Tuberculosis

NCT06081361

Q3 2028

N/ANot yet recruiting

RR-TB

NCT07198685

Clinical

Trials by Indication[1]

Cycloserine3 trials

Cycloserine rTMS Plasticity Augmentation in Depression

Completed·UUniversity of Calgary·Phase 1·NCT03511599·12 enrolled

Cycloserine rTMS Plasticity Augmentation

Completed·UUniversity of Calgary·Phase 1·NCT03432689·12 enrolled

Repeated iTBS Cycloserine Motor Plasticity

Completed·UUniversity of Calgary·Phase 2·NCT05081986·20 enrolled

Tuberculosis1 trial

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled

Smoking Behavior1 trial

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

Completed·YYale University·N/A·NCT00633256·20 enrolled

Opioid Dependence1 trial

Neurobiology of Opioid Dependence: 3 - 3

Withdrawn·YYale University·Phase 2·NCT00000194

Methadone1 trial

Drug Discrimination in Methadone-Maintained Humans Study 1

Completed·UUniversity of Arkansas·Phase 1·NCT00593463·40 enrolled

6 more indications

Treatment1 trial

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed·HHuashan Hospital·N/A·NCT04717908·89 enrolled

RR-TB1 trial

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

Not yet recruiting·WWuhan Pulmonary Hospital·N/A·NCT07198685·52 enrolled

Pulmonary Tuberculosis1 trial

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000796·525 enrolled

Multidrug-Resistant Tuberculosis1 trial

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Unknown status·—·Phase 4·NCT05306223·212 enrolled

Sleep Apnea1 trial

Cycloserine in the Treatment of Sleep Apnea

Terminated·UUniversity of Manitoba·Phase 1·NCT02735694·18 enrolled

Smoking Cessation1 trial

Investigation of Cycloserine as a Smoking Cessation Treatment

Completed·—·Phase 1·NCT01062932·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Cycloserine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cycloserine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cycloserine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Calgary

Cycloserine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Trials by Indication[1]

Cycloserine3 trials

Tuberculosis1 trial

Smoking Behavior1 trial

Opioid Dependence1 trial

Methadone1 trial

Treatment1 trial

RR-TB1 trial

Pulmonary Tuberculosis1 trial

Multidrug-Resistant Tuberculosis1 trial

Sleep Apnea1 trial

Smoking Cessation1 trial

References

Drug Info

Quick Facts

Related News